Glycosaminoglycan Replacement Therapy with Intravesical Instillations of Combined Hyaluronic Acid and Chondroitin Sulfate in Patients with Recurrent Cystitis, Post-radiation Cystitis and Bladder Pain Syndrome: A Narrative Review.
Bladder pain syndrome
Cystitis
Glycosaminoglycans
Interstitial cystitis
Intravesical instillation
Urinary tract infections
Journal
Pain and therapy
ISSN: 2193-8237
Titre abrégé: Pain Ther
Pays: New Zealand
ID NLM: 101634491
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
14
08
2023
accepted:
18
10
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
aheadofprint
Résumé
Defects in the glycosaminoglycan layer (GAG) of the bladder mucosa have been identified as a significant contributor to the pathogenesis and clinical progression of chronic inflammatory diseases of the bladder, such as post-radiation cystitis, bladder pain syndrome and recurrent urinary tract infections. This narrative review aims to explore the contemporary evidence on the role of GAG reconstitution with intravesical installations of hyaluronic acid and chondroitin sulfate in the management of those patients, with a goal to provide valuable insights for clinical practice. The reviewed studies consistently demonstrate that GAG reconstitution can result in varying degrees of clinical improvement in patients with post-radiation cystitis, bladder pain syndrome and recurrent urinary tract infections, and is associated with a very favorable safety profile. While the available evidence is growing, its level is still limited, mainly by relatively low number of randomized controlled trials, with small sample sizes. Further research with larger, well-designed trials is needed to solidify the findings and optimize the clinical application of GAG reconstitution.
Identifiants
pubmed: 37917298
doi: 10.1007/s40122-023-00559-1
pii: 10.1007/s40122-023-00559-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans—a review. Neurourol Urodyn. 2013;32(1):9–18.
pubmed: 22782909
doi: 10.1002/nau.22256
Lazzeri M, Hurle R, Casale P, Buffi N, Lughezzani G, Fiorini G, Peschechera R, Pasini L, Zandegiacomo S, Benetti A, Taverna G, Guazzoni G, Barbagli G. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Ther Adv Urol. 2016;8(2):91–9.
pubmed: 27034722
doi: 10.1177/1756287215621234
Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol. 2011;3(5):223–32.
pubmed: 22046200
pmcid: 3199589
doi: 10.1177/1756287211418723
Kanai AJ. Afferent mechanism in the urinary tract. Handb Exp Pharmacol. 2011;202:171–205.
doi: 10.1007/978-3-642-16499-6_9
Arms L, Vizzard MA. Neuropeptides in lower urinary tract function. Handb Exp Pharmacol. 2011;202:395–423.
doi: 10.1007/978-3-642-16499-6_19
Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet. 1990;171(6):493–6.
pubmed: 2244283
Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. BJU Int. 2008;101(Suppl 3):2–6.
pubmed: 18307678
doi: 10.1111/j.1464-410X.2008.07493.x
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;8(113 Suppl 1A):5S-13S.
doi: 10.1016/S0002-9343(02)01054-9
Ikäheimo R, Siitonen A, Heiskanen T, Kärkkäinen U, Kuosmanen P, Lipponen P, Mäkelä PH. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22(1):91–9.
pubmed: 8824972
doi: 10.1093/clinids/22.1.91
Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653–60.
pubmed: 21139641
doi: 10.1038/nrurol.2010.190
Vahlensieck W, Perepanova T, Bjerklund Johansen TE, Tenke P, Naber KG, Wagenlehner FE. Management of Uncomplicated Recurrent Urinary Tract Infections. Eur Urol Suppl. 2016;15(4):95–101.
doi: 10.1016/j.eursup.2016.04.007
Stamey TA. Recurrent urinary tract infections in female patients: an overview of management and treatment. Rev Infect Dis. 1987;9(2):S195-210.
pubmed: 3554458
doi: 10.1093/clinids/9.Supplement_2.S195
Schaeffer AJ. Recurrent urinary tract infections in women. Pathogenesis Manag Postgrad Med. 1987;81(3):51–8.
doi: 10.1080/00325481.1987.11699724
Fowler JE Jr. Urinary tract infections in women. Urol Clin North Am. 1986;13(4):673–83.
pubmed: 3535209
doi: 10.1016/S0094-0143(21)00271-8
Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007;4(12): e329.
pubmed: 18092884
pmcid: 2140087
doi: 10.1371/journal.pmed.0040329
Poggi MM, Johnstone PA, Conner RJ. Glycosaminoglycan content of human bladders. A method of analysis using cold-cup biopsies. Urol Oncol. 2000;5(5):234–7.
pubmed: 10973714
doi: 10.1016/S1078-1439(00)00074-0
Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology. 1997;49(5A Suppl):111–3.
pubmed: 9146012
doi: 10.1016/S0090-4295(97)00183-0
Parsons CL. Epithelial coating techniques in the treatment of interstitial cystitis. Urology. 1997;49(5A Suppl):100–4.
pubmed: 9146009
doi: 10.1016/S0090-4295(97)00180-5
Cicione A, Cantiello F, Ucciero G, Salonia A, Madeo I, Bava I, Aliberti A, Damiano R. Restoring the glycosaminoglycans layer in recurrent cystitis: experimental and clinical foundations. Int J Urol. 2014;21(8):763–8.
pubmed: 24640993
doi: 10.1111/iju.12430
Neugent ML, Hulyalkar NV, Kumar A, Xing C, Zimmern PE, Shulaev V, De Nisco NJ. Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women. ACS Infect Dis. 2023;9(4):1022–32.
pubmed: 36942838
pmcid: 10111421
doi: 10.1021/acsinfecdis.3c00027
Naber KG, Bonkat G, Wagenlehner FME. The EAU and AUA/CUA/SUFU Guidelines on Recurrent Urinary Tract Infections: What is the Difference? Eur Urol. 2020;78(5):645–6.
pubmed: 32616407
doi: 10.1016/j.eururo.2020.06.032
Tasdemir S, Tasdemir C, Vardi N, Yakupogullari Y, Duman Y, Parlakpinar H, Sagir M, Acet A. Intravesical hyaluronic acid and chondroitin sulfate alone and in combination for urinary tract infection: assessment of protective effects in a rat model. Int J Urol. 2012;19(12):1108–12.
pubmed: 22852837
doi: 10.1111/j.1442-2042.2012.03109.x
Damiano R, Quarto G, Bava I, Ucciero G, De Domenico R, Palumbo MI, Autorino R. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59(4):645–51.
pubmed: 21272992
doi: 10.1016/j.eururo.2010.12.039
Damiano R, Quarto G, Bava I, Ucciero G, De Domenico R, Palumbo MI, Autorino R. Corrigendum to "Prevention of Recurrent Urinary Tract Infections by Intravesical Administration of Hyaluronic Acid and Chondroitin Sulphate: A Placebo-Controlled Randomised Trial [Eur Urol 2011;59:645–51]. Eur Urol. 2011;60(1):193.
pubmed: 27989530
doi: 10.1016/j.eururo.2011.03.031
De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012;23(12):1707–13.
pubmed: 22614285
doi: 10.1007/s00192-012-1794-z
Torella M, Schettino MT, Salvatore S, Serati M, De Franciscis P, Colacurci N. Intravesical therapy in recurrent cystitis: a multi-center experience. J Infect Chemother. 2013;19(5):920–5.
pubmed: 23649671
doi: 10.1007/s10156-013-0609-6
Cicione A, Cantiello F, Ucciero G, Salonia A, Torella M, De Sio M, Autorino R, Carbone A, Romancik M, Tomaskin R, Damiano R. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey. Can Urol Assoc J. 2014;8(9–10):E721–7.
pubmed: 25408813
pmcid: 4216305
doi: 10.5489/cuaj.1989
Gugliotta G, Calagna G, Adile G, Polito S, Saitta S, Speciale P, Palomba S, Perino A, Granese R, Adile B. Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventing recurrent bacterial cystitis? A multicenter case control analysis. Taiwan J Obstet Gynecol. 2015;54(5):537–40.
pubmed: 26522106
doi: 10.1016/j.tjog.2015.03.005
Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, Morgia G, Fragalà E, Roman T, Bernat M, Guazzoni G, Tarricone R, Lazzeri M. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open. 2016;6(3): e009669.
pubmed: 27033958
pmcid: 4823394
doi: 10.1136/bmjopen-2015-009669
De Vita D, Antell H, Giordano S. Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent bacterial cystitis in adult women: a meta-analysis. Int Urogynecol J. 2013;24(4):545–52.
pubmed: 23129247
doi: 10.1007/s00192-012-1957-y
Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J. 2018;29(7):933–42.
pubmed: 29181550
doi: 10.1007/s00192-017-3508-z
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.
EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, the Netherlands 2022. ISBN 978-94-92671-16-5
Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, Oberpenning F, de C Williams AC; European Association of Urology. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35–48
Konkle KS, Berry SH, Elliott MN, Hilton L, Suttorp MJ, Clauw DJ, Clemens JQ. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol. 2012;187(2):508–12.
pubmed: 22177158
doi: 10.1016/j.juro.2011.10.040
Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.
pubmed: 21683389
pmcid: 3513327
doi: 10.1016/j.juro.2011.03.132
Han XM, Wu XH, Li B, Pan F, Li WC, Liu SL, Zeng FQ, Chen M. The effects of intravesical therapy with hyaluronic acid for painful bladder syndrome: Preliminary Chinese experience and systematic review. Taiwan J Obstet Gynecol. 2015;54(3):240–7.
pubmed: 26166334
doi: 10.1016/j.tjog.2014.09.007
Parsons CL. The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU Int. 2011;107(3):370–5.
pubmed: 21176078
doi: 10.1111/j.1464-410X.2010.09843.x
Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994;12(1):3–10.
pubmed: 8012413
doi: 10.1007/BF00182044
Danacioglu YO, Erol B, Ozkanli S, Yildirim A, Atis RG, Silay MS, Caskurlu T. Comparison of Intravesical Hyaluronic Acid, Chondroitin Sulfate, and Combination of Hyaluronic Acid-Chondroitin Sulfate Therapies in Animal Model of Interstitial Cystitis. Int Neurourol J. 2021;25(1):42–50.
pubmed: 33504136
pmcid: 8022172
doi: 10.5213/inj.1938176.088
Rooney P, Ryan C, McDermott BJ, Dev K, Pandit A, Quinlan LR. Effect of Glycosaminoglycan Replacement on Markers of Interstitial Cystitis In Vitro. Front Pharmacol. 2020;3(11): 575043.
doi: 10.3389/fphar.2020.575043
Stellavato A, Pirozzi AVA, Diana P, Reale S, Vassallo V, Fusco A, Donnarumma G, De Rosa M, Schiraldi C. Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation. PLoS ONE. 2019;14(6): e0218475.
pubmed: 31237905
pmcid: 6592599
doi: 10.1371/journal.pone.0218475
Stavropoulos M, Thakare N, Venieris P, Liakouras C, Deliveliotis C, Chrisofos M. The use of intravesical hyaluronic acid in the management of symptomatic premenopausal women with pseudomembranous trigonitis: Are symptoms related to cystoscopy and pathological findings? Low Urin Tract Symptoms. 2022;14(1):57–63.
pubmed: 34476901
doi: 10.1111/luts.12410
Lin CJ, Liu CK, Hsieh HY, Chen MJ, Tsai CP. Changes in Cystoscopic Findings after Intravesical Hyaluronic Acid Instillation Therapy in Patients with Interstitial Cystitis. Diagnostics (Basel). 2022;12(8):2009.
pubmed: 36010358
doi: 10.3390/diagnostics12082009
Porru D, Leva F, Parmigiani A, Barletta D, Choussos D, Gardella B, Daccò MD, Nappi RE, Allegri M, Tinelli C, Bianchi CM, Spinillo A, Rovereto B. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2012;23(9):1193–9.
pubmed: 21904840
doi: 10.1007/s00192-011-1546-5
Cervigni M, Natale F, Nasta L, Mako A. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: long-term treatment results. Int Urogynecol J. 2012;23(9):1187–92.
pubmed: 22569687
doi: 10.1007/s00192-012-1742-y
Giberti C, Gallo F, Cortese P, Schenone M. Combined intravesical sodium hyaluronate/chondroitin sulfate therapy for interstitial cystitis/bladder pain syndrome: a prospective study. Ther Adv Urol. 2013;5(4):175–9.
pubmed: 23904856
pmcid: 3721440
doi: 10.1177/1756287213490052
Gülpınar O, Kayış A, Süer E, Gökçe Mİ, Güçlü AG, Arıkan N. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J. 2014;8(9–10):E610–4.
pubmed: 25295131
pmcid: 4164548
doi: 10.5489/cuaj.2036
Cervigni M, Sommariva M, Tenaglia R, Porru D, Ostardo E, Giammò A, Trevisan S, Frangione V, Ciani O, Tarricone R, Pappagallo GL. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36(4):1178–86.
pubmed: 27654012
doi: 10.1002/nau.23091
Arslan B, Gönültaş S, Gökmen E, Özman O, Avci MA, Özdemir E. Outcomes of intravesical chondroitin-sulfate and combined hyaluronic-acid/chondroitin-sulfate therapy on female sexual function in bladder pain syndrome. Int Urogynecol J. 2019;30(11):1857–62.
pubmed: 31254047
doi: 10.1007/s00192-019-04036-2
Sherif H, Sebay A, Kandeel W, Othman T, Fathi A, Mohey A, Eshazly A. Safety and efficacy of Intravesical hyaluronic acid/chondroitin sulfate in the treatment of refractory painful bladder syndrome. Turk J Urol. 2018;45(4):296–301.
pubmed: 30475699
pmcid: 6619837
doi: 10.5152/tud.2018.63600
Keane J, Young N, Goh J, Atherton M, Yin J, Moore K, Hall P, Higgs P, Leitch A, Lee J, Rosamilia A. A comparison of two intravesical bladder instillations for interstitial cystitis/bladder pain syndrome. Eur J Obstet Gynecol Reprod Biol. 2021;256:230–4.
pubmed: 33248378
doi: 10.1016/j.ejogrb.2020.10.060
Di XP, Luo DY, Jin X, Zhao WY, Li H, Wang KJ. Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis. Int Urogynecol J. 2021. https://doi.org/10.1007/s00192-020-04659-w . (Epub ahead of print).
doi: 10.1007/s00192-020-04659-w
pubmed: 33638677
Liu S, Zhang C, Peng L, Lu Y, Luo D. Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials. Int Urogynecol J. 2020. https://doi.org/10.1007/s00192-020-04490-3 . (Epub ahead of print).
doi: 10.1007/s00192-020-04490-3
pubmed: 32886173
pmcid: 7679264
Zhang W, Deng X, Liu C, Wang X. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Int Urogynecol J. 2017;28(4):515–25. https://doi.org/10.1007/s00192-016-3079-4 .
doi: 10.1007/s00192-016-3079-4
pubmed: 27614759
Barua JM, Arance I, Angulo JC, Riedl CR. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2016;27(8):1137–47.
pubmed: 26590137
doi: 10.1007/s00192-015-2890-7
Ghaith AF, Radwan MH, Rashed Taha M, Elbendary MA, Al Damhogy ME, Hagras AM. Evaluation of pain and quality of life after hyaluronic acid instillation in addition to botulinum toxin-A injection in women with refractory Interstitial Cystitis/Painful Bladder Syndrome: A pilot study. Arch Ital Urol Androl. 2022;94(4):447–50.
pubmed: 36576459
doi: 10.4081/aiua.2022.4.447
Pyo JS, Cho WJ. Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder Syndrome. Cell Physiol Biochem. 2016;39(4):1618–25.
pubmed: 27627755
doi: 10.1159/000447863
Gülpınar Ö, Esen B, Kayış A, Gökçe Mİ, Süer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018;37(1):257–62.
pubmed: 28480984
doi: 10.1002/nau.23284
Özkıdık M. Assessment of long-term intravesical hyaluronic acid, chondroitin sulfate and combination therapy for patients with bladder pain syndrome. Cent European J Urol. 2019;72(3):270–5.
pubmed: 31720029
pmcid: 6830487
Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev Urol. 2010;7(4):206–14.
pubmed: 20212517
doi: 10.1038/nrurol.2010.23
Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1257–80.
pubmed: 7713787
doi: 10.1016/0360-3016(94)00431-J
Do V, Choo R, Deboer G, Herschorn S, Danjoux C, Chen CH, Barak I. Urodynamic findings 3 months after radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma. BJU Int. 2002;90(1):62–7.
pubmed: 12081772
doi: 10.1046/j.1464-410X.2002.02813.x
Levenback C, Eifel PJ, Burke TW, Morris M, Gershenson DM. Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol. 1994;55(2):206–10.
pubmed: 7959285
doi: 10.1006/gyno.1994.1278
Blaivas JG, Weiss JP, Jones M. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer. BJU Int. 2006;98(6):1233–7.
pubmed: 17125481
doi: 10.1111/j.1464-410X.2006.06491.x
Lin HH, Sheu BC, Lo MC, Huang SC. Abnormal urodynamic findings after radical hysterectomy or pelvic irradiation for cervical cancer. Int J Gynaecol Obstet. 1998;63(2):169–74.
pubmed: 9856324
doi: 10.1016/S0020-7292(98)00158-1
Parkin DE, Davis JA, Symonds RP. Urodynamic findings following radiotherapy for cervical carcinoma. Br J Urol. 1988;61(3):213–7.
pubmed: 3359124
doi: 10.1111/j.1464-410X.1988.tb06381.x
Lobo N, Kulkarni M, Hughes S, Nair R, Khan MS, Thurairaja R. Urologic complications following pelvic radiotherapy. Urology. 2018;122:1–9.
pubmed: 30036617
doi: 10.1016/j.urology.2018.07.017
Martinez Rodriguez RH, Bayona Arenas S, Ibarz SL. Tratamiento con ácido hialurónico de la hematuria asociada a cistopatía rádica [Hyaluronic acid instillation as treatment of haematuria due to radiation induced cystitis]. Med Clin (Barc). 2014;143(5):230–1.
pubmed: 24120105
doi: 10.1016/j.medcli.2013.07.015
Sommariva ML, Sandri SD, Ceriani V. Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis. Minerva Urol Nefrol. 2010;62(2):145–50.
pubmed: 20562794
Shao Y, Lu GL, Shen ZJ. Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis. BJU Int. 2012;109(5):691–4.
pubmed: 21895939
doi: 10.1111/j.1464-410X.2011.10550.x
Nordling J, van Ophoven A. Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung. 2008;58(7):328–35.
pubmed: 18751498
Baboudjian M, Fourmarier M, Clement C, Cherasse A, Graziana JP, Bentaleb Y, Rouscoff Y, Ducrocq S, Gondran-Tellier B, Saussine C. Intravesical instillation of high molecular weight sodium hyaluronate in radiation-induced cystitis: a prospective pilot study. World J Urol. 2022;40(1):141–6.
pubmed: 34550425
doi: 10.1007/s00345-021-03837-9
Gacci M, Saleh O, Giannessi C, Detti B, Livi L, Monteleone Pasquetti E, Masoni T, Finazzi Agro E, Li Marzi V, Minervini A, Carini M, Gravas S, Oelke M, Serni S. Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. BMC Urol. 2015;7(15):65.
doi: 10.1186/s12894-015-0046-1
Gacci M, Saleh O, Giannessi C, Chini T, Della Camera PA, Detti B, Livi L, Finazzi Agro E, Li Marzi V, Minervini A, Carini M, Oelke M, Gravas S, Serni S. Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study. Clin Genitourin Cancer. 2016;14(5):444–9.
pubmed: 26953222
doi: 10.1016/j.clgc.2016.01.016
Sommariva ML, Lazzeri M, Abrate A, Guazzoni G, Sandri S, Montorsi F. Intravesical Hyaluronic Acid and Chondroitin Sulphate Improve Symptoms and Quality of Life in Patients with Late Radiation Tissue Cystitis: An Investigative Pilot Study. Eur J Inflam. 2014;12:177–85.
doi: 10.1177/1721727X1401200117
Sanguedolce F, Meneghetti I, Bevilacqua G, Montaño B, Martínez C, Territo A, Balaña J, Palou J, Breda A. Intravesical instillation with glycosaminoglycan replacement treatment in patients suffering radiation-induced haemorrhagic cystitis: When and which patients can benefit most from it? Urol Oncol. 2022;40(7):344.e19-344.e25.
pubmed: 35400568
doi: 10.1016/j.urolonc.2022.02.013
Hazewinkel MH, Stalpers LJ, Dijkgraaf MG, Roovers JP. Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies. Int Urogynecol J. 2011;22(6):725–30.
pubmed: 21365332
pmcid: 3097354
doi: 10.1007/s00192-010-1357-0
Palou Redorta J, Sanguedolce F, Sancho Pardo G, Romancik M, Vittori G, Minervini A, Di Maida F, Lunik R, Colombo R, Serretta V, Çetinel B, Bini V, Corradengo D, Lazzeri M. Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC): A Randomised Controlled Study. Eur Urol Open Sci. 2021;26:45–54.
doi: 10.1016/j.euros.2021.01.016
King GK, Goodes LM, Hartshorn C, Thavaseelan J, Jonescu S, Watts A, Rawlins M, Woodland P, Synnott EL, Barrett T, Hayne D, Boan P, Dunlop SA. Intravesical hyaluronic acid with chondroitin sulphate to prevent urinary tract infection after spinal cord injury. J Spinal Cord Med. 2022;6:1–7.
Cicek N, Yildiz N, Alpay H. Intravesical hyaluronic acid treatment in recurrent urinary tract infections in children with spina bifida and neurogenic bladder. J Pediatr Urol. 2020;16(3):366.e1-366.e5.
pubmed: 32197933
doi: 10.1016/j.jpurol.2020.02.009
Dinh A, Duran C, Hamami K, Afif M, Bonnet F, Donay JL, Lafaurie M, Chartier-Kastler E. Hyaluronic Acid and Chondroitin Sulphate Treatment for Recurrent Severe Urinary Tract Infections due to Multidrug-Resistant Gram-Negative Bacilli in a Patient With Multiple Sclerosis: Case Report and Literature Review. Open Forum Infect Dis. 2022;9(7):ofac245.
pubmed: 35855005
pmcid: 9280323
doi: 10.1093/ofid/ofac245
Topazio L, Miano R, Maurelli V, Gaziev G, Gacci M, Iacovelli V, Finazzi-Agrò E. Could hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study. BMC Urol. 2014;13(14):64.
doi: 10.1186/1471-2490-14-64
Imperatore V, Creta M, Di Meo S, Buonopane R, Longo N, Fusco F, Spirito L, Imbimbo C, Mirone V. Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory bacillus Calmette-Guerin-induced chemical cystitis: Preliminary experience with one-year follow-up. Arch Ital Urol Androl. 2018;90(1):11–4.
pubmed: 29633792
doi: 10.4081/aiua.2018.1.11
Torella M, Del Deo F, Grimaldi A, Iervolino SA, Pezzella M, Tammaro C, Gallo P, Rappa C, De Franciscis P, Colacurci N. Efficacy of an orally administered combination of hyaluronic acid, chondroitin sulfate, curcumin and quercetin for the prevention of recurrent urinary tract infections in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2016;207:125–8.
pubmed: 27838537
doi: 10.1016/j.ejogrb.2016.10.018
Schiavi MC, Porpora MG, Vena F, Prata G, Sciuga V, D’Oria O, Di Tucci C, Savone D, Aleksa N, Giannini A, Nusiner MP, Zullo MA, Muzii L, Benedetti PP. Orally Administered Combination of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin in the Prevention of Postcoital Recurrent Urinary Tract Infections: Analysis of 98 Women in Reproductive Age After 6 Months of Treatment. Female Pelvic Med Reconstr Surg. 2019;25(4):309–12.
pubmed: 29389678
doi: 10.1097/SPV.0000000000000560
Manfredi C, Spirito L, Calace FP, Balsamo R, Terribile M, Stizzo M, Romano L, Napolitano L, Califano G, Cirillo L, Fusco GM, Rosati C, Quattrone C, Sciorio C, Creta M, Longo N, De Sio M, Arcaniolo D. Oral Preparation of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin (Ialuril® Soft Gels) for the Prevention of LUTS after Intravesical Chemotherapy. Pathophysiology. 2022;29(3):365–437.
pubmed: 35893598
pmcid: 9326532
doi: 10.3390/pathophysiology29030028